Aetna Breast Reconstructive Surgery Coverage

Primary medical necessity

Aetna considers reconstructive breast surgery medically necessary when ANY of the following are met:

Medical necessity principal criteria: After a medically necessary mastectomy; OR After a medically necessary lumpectomy that results in a significant deformity (including surgery for treatment or prophylaxis of breast cancer or for chronic, severe fibrocystic breast disease unresponsive to medical therapy).

Supported by policy section 'Medical Necessity'

Covered reconstructive procedures

Medically necessary procedures include (when criteria above met):

List of covered procedures: Capsulectomy; Capsulotomy; Implantation of FDA‑approved internal breast prosthesis; Mastopexy; Insertion of breast prostheses; Use of tissue expanders; Reconstruction with latissimus dorsi (LD) flap; Ruben's flap; Superficial inferior epigastric perforator (SIEP) flap; Superior or inferior gluteal free flap; Transverse upper gracilis (TUG) flap; Transverse rectus abdominis myocutaneous (TRAM) flap; Deep inferior epigastric perforator (DIEP) flap; Superficial inferior epigastric artery (SIEA) flap; Superior gluteal artery perforator (SGAP) flap; Profunda artery perforator flap; Similar procedures including skin‑sparing techniques; Harvesting (lipectomy or liposuction) and grafting of autologous fat as replacement for implants or to fill defects after breast conservation or other reconstructive techniques; Associated nipple and areolar reconstruction and tattooing; Reduction or augmentation mammoplasty and related reconstructive procedures on the unaffected side for symmetry.

Enumerated list of medically necessary procedures

Medically necessary acellular dermal matrices

The following acellular dermal matrices are considered medically necessary:

ADM list: Alloderm (LifeCell Corp.); Alloderm‑RTU (LifeCell Corp.); Cortiva (formerly AlloMax/NeoForm); DermACELL (Novadaq Technologies); DermaMatrix (Musculoskeletal Transplant Foundation/Synthes CMF); FlexHD (Musculoskeletal Transplant Foundation/Ethicon); Strattice (LifeCell Corp.); SurgiMend (TEI Biosciences).

Named products supported as medically necessary

Cosmetic exclusion and exceptions

Cosmetic stance and exceptions:

Cosmetic exclusion: Breast reconstructive surgery to correct breast asymmetry is considered cosmetic except when: (1) surgical correction of chest wall deformity causing functional deficit in Poland syndrome when CPB 0272 criteria are met; OR (2) repair of breast asymmetry due to a medically necessary mastectomy or medically necessary lumpectomy that results in a significant deformity. In these exceptions, procedures on the unaffected breast to achieve symmetry (including areolar/nipple reconstruction and tattooing, augmentation with FDA‑approved implants when needed, implant removal/reimplantation for symmetry, reduction mammoplasty or mastopexy, capsulectomy, capsulotomy, and reconstructive revisions) are medically necessary.

Cosmetic exclusion with explicit exceptions

Experimental / investigational

The following are considered experimental and investigational (insufficient evidence):

Experimental items: Artia Reconstructive Tissue Matrix; Biodesign Nipple Reconstruction Cylinder; Body lift perforator flap technique for breast reconstruction; Nerve coaptation for improvement of sensation following breast reconstruction; SimpliDerm for breast reconstruction; Three‑dimensional (3D) volumetric imaging and reconstruction of breast or axillary lymph node.

Enumerated experimental/investigational procedures

Use of 3D volumetric imaging/printing for planning breast reconstruction

Evidence and findings reported in observational and small prospective studies — no standardized coverage criteria provided in these chunks.

3D imaging/printing evidence summary: 3D surface imaging correlates with MRI for breast volume estimation but may not capture chest wall contour; combining 3D surface scan with MRI can overcome limitations (chunks 55). Retrospective cohort data (n=56) showed a 3D‑volume‑based prediction model for ideal implant size with strong performance (R2 = 0.900) and better prediction than mastectomy specimen weight (chunk 57). 3D‑printed, patient‑specific DIEP templates identified perforators accurately and reduced intraoperative perforator identification time in a 20‑patient prospective series; authors reported no immediate flap‑related complications but called for further validation and long‑term outcome assessment (chunk 61).

Studies are small and heterogeneous; no standardized coverage criteria are established.

Nerve coaptation/neurotization for sensation improvement

Multiple observational studies, cadaver dissections, and systematic reviews report improved sensory recovery with neurotization techniques, but heterogeneity and limited standardized outcome measures remain.

Neurotization evidence summary: Anatomical cadaver studies describe harvesting donor sensory intercostal nerve branches and using allografts to bridge gaps for flap neurotization (chunks 63–64). Small clinical series report preserved or improved nipple‑areolar complex and breast sensation with nerve preservation/grafting in implant and autologous reconstructions (eg, Peled and Peled: preserved NAC 2‑point discrimination in 87% of breasts; chunk 67). Systematic reviews (including 23 studies) report pooled neurotization success rates around 90.6% and overall trends toward earlier and superior sensory recovery, but note wide heterogeneity in techniques and sensory testing and call for standardized prospective studies and PROMs such as the BREAST‑Q (chunks 70,73).

Promising but heterogeneous evidence; further high‑quality standardized studies recommended before declaring standard of care.

Aetna considers breast reconstructive surgery to correct breast asymmetry to be cosmetic in all situations except the explicitly listed exceptions. Exceptions include: (1) surgical correction of chest wall deformity causing a functional deficit in Poland syndrome when criteria in CPB 0272 are met; and (2) repair of breast asymmetry that is the direct result of a medically necessary mastectomy or lumpectomy that produces a significant deformity. In those exception cases, procedures on the unaffected breast to achieve symmetry (for example, areolar/nipple reconstruction or tattooing, augmentation with an FDA‑approved internal breast prosthesis, implant removal/re‑implantation, reduction mammoplasty, mastopexy, capsulectomy, capsulotomy, and reconstructive revisions) are considered medically necessary when performed to produce a symmetrical appearance.

Autologous fat grafting (lipomodelling) is described as a technique to improve contour or restore volume but has variable effectiveness and important safety concerns. Case series report wide variability in outcomes (substantial improvement reported in 21%–86.5% of patients) and an approximate 7% rate of lipo‑necrotic lumps. These nodules, calcifications, cysts, and indurations can produce abnormalities on cancer screening and may impede future cancer detection; long‑term follow‑up and imaging (mammography, ultrasound, CT, MRI) are recommended after the procedure.

The “body lift” perforator flap technique — a layered or circumferential trunk donor approach to provide additional volume for autologous reconstruction in thin patients — has been reported in small case series but is currently judged to have insufficient evidence to support routine use for breast reconstruction. Major clinical reviews and UpToDate summaries do not describe this technique as a standard management option, and further well‑designed studies are needed to validate safety and outcomes.

Immediate expander‑implant breast reconstruction (EIBR) in patients with prior pre‑mastectomy external beam radiation therapy (XRT) is associated with substantially higher complication and failure rates compared with non‑irradiated patients. In one retrospective series, the EIBR failure rate was reported at 50.0% for the pre‑operative XRT group versus 13.3% in controls (p = 0.044). The authors recommend that patients with a history of pre‑mastectomy radiation strongly consider autologous reconstruction to avoid the higher risk of complications and implant loss with EIBR.

Evidence summaries and recent reviews note that 3D volumetric imaging and 3D‑printed templates have been evaluated in small observational series and may assist preoperative planning (for example, improved implant sizing prediction and reduced intraoperative perforator identification time). However, an UpToDate overview of breast reconstruction (Nahabedian, 2021) does not list 3D volumetric imaging among standard management tools, reflecting limited adoption in mainstream clinical references and the need for further validation before routine use.

The policy lists nerve coaptation / neurotization among procedures for which the current evidence is insufficient to establish clear effectiveness (classified as experimental and investigational in this CPB). Within the provided excerpt there is no explicit coverage exclusion or definitive payer stance on neurotization beyond its inclusion in the experimental/investigational list; the background summarizes promising but heterogeneous study results and calls for additional standardized research.

The excerpt contains no specific site‑exit coverage exclusions for additional procedures beyond those enumerated in the policy. The final chunk is a site‑exit disclaimer and does not state any further coverage restrictions or exclusions beyond the policy text already cited.

The policy references specific procedure and technology codes in its coverage discussion. Notably, CPT code 0694T (3‑dimensional volumetric imaging/reconstruction) is identified in the document as an item of concern (listed under experimental/not covered in the CPB), and nerve graft/allograft procedure codes 64910–64913 are discussed in the context of nerve repair/coaptation techniques. These code references are provided to guide billing and to indicate that these technologies/procedures are addressed in the policy.

Although neurotization (nerve coaptation) is discussed in the background and listed among experimental/investigational procedures in the policy, the excerpt does not contain any explicit statement designating neurotization procedures as not medically necessary. The document instead summarizes the existing evidence and notes heterogeneity and the need for standardized outcome measurement before establishing a definitive coverage determination.

Coding

Covered CPT Codes (if selection criteria are met)CPTCovered

11920	Tattooing, intradermal introduction of insoluble opaque pigments to correct color defects of skin, including micropigmentation; 6.0 sq cm or less.
11921	6.1 to 20.0 sq cm.
11922	each additional 20.0 sq cm (List separately in addition to code for primary procedure).
11950	Subcutaneous injection of filling material (eg, collagen).
11971	Removal of tissue expander without insertion of implant.
15769	Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia).
15771	Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate.
15772	each additional 50 cc injectate, or part thereof.
15773	Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate.
15774	each additional 25 cc injectate, or part thereof.

1–10 of 31

1/4

CPT Codes Not Covered / ExperimentalCPTNot Covered

0694T	3-dimensional volumetric imaging and reconstruction of breast or axillary lymph node tissue, each excised specimen.
64910	Nerve repair; with synthetic conduit or vein allograft (eg, nerve tube), each nerve.
64911	with autogenous vein graft (includes harvest of vein graft), each nerve.
64912	with nerve allograft, each nerve, first strand (cable).
64913	with nerve allograft, each additional strand (List separately in addition to code for primary procedure).

Covered HCPCS Codes (if selection criteria are met)HCPCSCovered

C1781	Mesh (implantable) [Cortiva].
C1789	Prosthesis, breast (implantable).
C9358	Dermal substitute, native, non- denatured collagen, fetal bovine origin (SurgiMend collagen matrix), per 0.5 square centimeters.
C9360	Dermal substitute, native, non- denatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 square centimeters.
L8600	Implantable breast prosthesis, silicone or equal.
Q4116	Alloderm, per square centimeter.
Q4122	Dermacell, dermacell awm or dermacell awm porous, per square centimeter.
Q4128	Flex HD, Allopatch HD, or Matrix HD, per square centimeter.
Q4130	Strattice TM, per sq cm.
S2066	Breast reconstruction with gluteal artery perforator (GAP) flap, unilateral.

1–10 of 12

1/2

Covered ICD-10 Codes (if selection criteria are met)ICD-10Covered

C50.011 - C50.929	Malignant neoplasm of breast.
C79.81	Secondary malignant neoplasm of breast.
D05.00 - D05.92	Carcinoma in situ of breast.
N60.11 - N60.19	Diffuse cystic mastopathy [severe fibrocystic disease].
Z85.3	Personal history of malignant neoplasm of breast.
Z90.10 - Z90.13	Acquired absence of breast [following medically necessary mastectomy or lumpectomy resulting in significant deformity].

ICD-10 Not Covered / Other relatedICD-10Not Covered

R59.0 - R59.9	Enlarged lymph nodes.
Z42.1 - Z42.8	Encounter for plastic and reconstructive surgery following medical procedure or healed injury [breast reconstruction].

DIEP candidacy factors — clinical candidacy elements

Maximum TRAM skin paddleNo more than 70% of the TRAM flap skin paddle should be required for reconstruction

Perforator size and pulseAt least one perforating vessel >1 mm in diameter with a detectable pulse must be present

Smoking statusPatient should be a non-smoker (smoking increases flap complication risk)

Adequate abdominal fatSufficient abdominal fat is required to create the new breast (candidate similar to free TRAM criteria)

Caution for large-volume needsExercise caution for patients requiring large volume reconstruction due to risk of fat necrosis or hardening

Provider Actions & Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for covered reconstructive codes where the plan or member's benefit design specifies prior authorization. Providers should obtain prior authorization when applicable and submit appropriate clinical documentation supporting medical necessity.

Submit applicable CPT/HCPCS/ICD-10 codes listed in the policy and ensure selection criteria are met (see Applicable codes section).
Obtain prior authorization when the member’s plan requires it for reconstructive procedures.

Documentation Required

ADM Use — Documentation Required

When acellular dermal matrices (ADMs) or biologic implants are used, document product selection and clinical rationale in the medical record. Include details that may affect complication risk and choice of material.

Record the specific ADM product (e.g., AlloDerm, DermACELL, Cortiva, SurgiMend) and lot if available.
Document indication for ADM use, anticipated benefit, and any product-specific considerations (e.g., prior radiation, infection risk).
Include intraoperative findings and how ADM contributed to reconstruction.

Billing Rule

Artia (porcine collagen mesh) — Coding/Coverage Note

Artia is classified by the FDA as a collagen mesh (porcine). CMS has stated Artia is not suitable for Level II HCPCS coding for ambulatory use and would be bundled for inpatient hospital payment; providers should be aware of coding and billing implications.

Artia: porcine collagen mesh; FDA classification as collagen mesh.
CMS (2019) guidance: not appropriate for Level II HCPCS coding for outpatient use; inpatient use may be bundled in hospital payment.
Contact payer coding services for billing guidance and consider pass-through coding avenues per CMS guidance.

Note

Prior Authorization Not Specified for Certain Adjuncts in Excerpt

The provided excerpt does not specify explicit prior authorization requirements for 3D printing/templates, neurotization (nerve coaptation), or some other adjunctive techniques. Providers should verify member-specific prior authorization requirements with the plan.

3D volumetric analysis, 3D-printed templates, and nerve coaptation procedures are discussed in evidence sections but no uniform prior authorization rule is stated in the excerpt.
Confirm prior authorization requirements with member’s benefit and local medical policy before scheduling.

Denial Risk

Autologous Fat Grafting — Safety Concerns

Autologous fat grafting carries safety concerns including formation of lipo-necrotic lumps, calcifications, cysts, and indurations that can impede future cancer detection. Patients should be counseled about these risks and followed long-term with appropriate imaging.

Document informed consent discussing risk of calcification, cyst formation, palpable induration, and potential impacts on breast cancer screening.
Plan and document post-procedure imaging and long-term follow-up (mammography, ultrasound, MRI as indicated).

Denial Risk

Radiation History — Increased EIBR Failure Risk

Prior radiation increases failure and complication risk for immediate expander-implant breast reconstruction (EIBR). Consider autologous reconstruction in patients with pre-mastectomy radiation and document radiation history in the record.

Document history and timing of external beam radiation therapy (pre- or post-operative).
Discuss increased risk of EIBR failure with the patient; document shared decision-making and consideration of autologous options.

Denial Risk

Obesity — Increased Complication Risk

Obesity is associated with higher rates of surgical and medical complications and re-operation after breast reconstruction. Document BMI and counsel regarding increased peri-operative risk; consider weight optimization when clinically appropriate.

Record BMI and discuss specific risks (higher wound complications, fat necrosis, re-operation rates).
Consider and document any preoperative optimization steps or rationale for proceeding despite elevated BMI.

Note

Evidence Summaries Present — Authorization Details Not Specified

The excerpt includes evidence and background summaries (e.g., ADM comparative studies, neurotization outcomes, 3D volumetric planning) but does not always translate these into explicit authorization or billing requirements. Providers should use the evidence to support medical necessity documentation where applicable.

When relying on evidence summaries to support authorization, include study-relevant clinical details in the request (e.g., prior radiation, flap type, complication risks).
If the evidence section suggests higher risk subgroups (e.g., smokers, prior XRT, high initial expander fill), document these factors in the clinical record.

Note

No Explicit Authorization/Denial Triggers in Excerpt

In the provided excerpt there are background and evidence sections without direct provider-action mandates. Where no explicit authorization or denial triggers are listed, providers should still document clinical rationale and confirm payer-specific requirements.

Examples include sections on neurotization and 3D planning where clinical evidence is described but no coverage rule is given.
Verify member coverage for adjunctive or emerging techniques.

Note

No Denial-Risk Statements in Administrative Links

The excerpt does not contain explicit denial-risk statements tied to external links or administrative content. External resources and site links are informational only.

Reference links (glossary, program provisions, disclosures) are provided for convenience and do not constitute coverage guidance.
For coverage determinations rely on the policy, benefit booklet, and payer prior authorization processes.

Documentation Required

Post-procedure Imaging and Follow-up — Document Plan

Post-procedure follow-up and imaging should be documented following autologous fat grafting and other reconstructive procedures. Long-term surveillance may include mammography, ultrasound (echography), CT, or MRI as clinically indicated.

Document a follow-up plan including timing and modality of imaging.
Record findings from postoperative imaging and any interventions prompted by imaging abnormalities.

Documentation Required

Volumetric Planning — Document Assessments

Pre-operative volumetric planning (3D surface imaging, MRI, mastectomy specimen weight) can support implant selection and improve symmetry. Document any volumetric assessments used to plan reconstruction.

Record method used for volumetric assessment (3D surface imaging, MRI, CTA, or mastectomy specimen weight) and results.
If 3D-printed molds or templates are used, document purpose, how they informed intraoperative decisions, and related outcomes.

Documentation Required

Suggested Clinical Documentation Elements

Suggested clinical documentation elements from studies include 3D surface imaging, mastectomy specimen weight, BREAST-Q scores, and perforator imaging (CTA) for flap planning. Include these when available to support medical necessity and expected outcomes.

Include objective pre- and post-operative assessments (3D volumes, mastectomy specimen weight).
Document patient-reported outcomes (BREAST-Q) when used.
For perforator flap planning, include CTA or other imaging reports and how they affected surgical approach.

Note

Use Evidence to Support Authorization Requests

The document excerpt provides evidence summaries on multiple adjuncts (ADMs, 3D planning, neurotization, fat grafting) but does not always stipulate coverage criteria for emerging products or techniques. Use evidence to inform clinical justification when requesting authorization.

When submitting prior authorization requests, include relevant codes and clinical rationale tied to policy-listed medically necessary indications.
No step therapy or sequencing requirements are specified in the provided excerpt; verify if member-specific benefits impose such requirements.

Note

Reference Resources

Reference resources and external links are provided in the excerpt for additional information on benefits, program provisions, and legal notices. These are informational and do not replace policy or benefit determinations.

Use the Aetna glossary and program provisions for definitions and benefit guidance.
For coverage decisions consult the full policy, member benefit booklet, and prior authorization tools.

Definitions

Autologous fat grafting (lipomodelling) — definition and steps

DefinitionHarvesting the patient’s own fat (commonly via syringe/cannula liposuction), processing (wash/centrifugation), and injecting into the breast to restore volume or correct contour defects

Typical donor sitesAbdomen, outer thigh, or flank

IndicationsUsed to repair contour defects or as an adjunct to other reconstruction techniques; less evidence for complete autologous reconstruction using fat alone

Safety and imaging considerationsMay cause fat resorption, lipo-necrotic lumps, calcifications or cysts that can complicate future cancer screening and require long-term imaging follow-up

DIEP flap — definition and characteristics

DefinitionA free flap using abdominal skin and fat supplied by deep inferior epigastric perforators that preserves abdominal muscle and fascia (no muscle taken)

Key characteristicRequires meticulous dissection of perforating vessels from muscle (perforator flap technique)

Donor requirementsCandidates need adequate abdominal fat similar to free TRAM criteria

Comparative benefitReduces abdominal wall morbidity compared to TRAM flaps (less donor-site muscle sacrifice)

Perfusion considerationsDIEP flaps may have less robust blood flow than standard TRAM; careful patient selection needed to minimize flap complications

Autologous fat grafting — transfer of adipose tissue, variable graft take and imaging considerations

DefinitionTransfer of the patient’s own adipose tissue into the breast to correct contour or volume defects

Graft survivalGraft take is variable with common early resorption; long-term survival of injected fat is uncertain and may necessitate multiple sessions

Complication risksAssociated with fat necrosis, lipo-necrotic lumps (~7% reported in case series), calcifications, cysts, indurations, and possible infection

Imaging implicationsInjected fat can create imaging abnormalities (mammography, CT, MRI) that complicate cancer screening; long-term imaging follow-up is recommended

Acellular dermal matrix (ADM) — biologic scaffold description and use

DefinitionAcellular dermal matrix (ADM) is a biologic soft-tissue scaffold derived from donor human or animal dermis that is processed to remove cells and used to reinforce soft tissue and support implants

SourcesHuman cadaveric, bovine (fetal/neonatal), or porcine-derived products are used

Role in reconstructionUsed as an adjunct in implant-based breast reconstruction to reinforce soft tissue, support implants, and facilitate implant-based techniques

Product variabilityDifferent ADMs are processed differently, with minor performance differences reported among products in comparative series

Stacked or SHAEP flaps — definition for using multiple flap components to increase volume

DefinitionUse of multiple pedicled or free flap components (stacked flaps or SHAEP flaps) to increase breast volume when single donor-site tissue is insufficient

Stacked flapsCombining two or more free flaps (e.g., bilateral or stacked DIEP/GAP) to achieve greater volume; reported flap survival rates high (e.g., 97.9% in one series)

SHAEP flapStacked hemi-abdominal extended perforator (SHAEP) flap combines hemi-abdominal pedicles (eg, DIEP plus lateral pedicle) to increase volume from a single donor site

Recipient vessel considerationsTechnique may be limited by need for adequate recipient vessels; antegrade and retrograde internal mammary vessels often used for anastomoses

Acellular dermal matrix — additional ADM background

ConceptADM is a biologic soft-tissue scaffold processed to remove cellular components, allowing host cellular and vascular ingrowth

Clinical useCommon adjunct in implant-based reconstruction; early literature focused on AlloDerm but multiple products are in use

Comparative dataComparative series suggest no major differences in outcomes among ADMs, though product-specific complication profiles (eg, seroma rates) have been reported

Documentation relevanceADM selection, indication, and patient risk factors may affect complication profile and should be documented for review

Artia — definition and regulatory/classification notes

DefinitionArtia is a porcine-derived reconstructive tissue matrix intended as a soft tissue patch to reinforce soft tissue and bridge or repair damaged soft tissue membranes

Regulatory classificationFDA-classified as a collagen mesh

Coding/classification notePer CMS, Artia is not suitable for Level II HCPCS coding and is typically bundled into hospital inpatient payments; CMS referred manufacturer for pass-through coding consideration

Evidence statusPreclinical and limited studies exist; clinical applicability requires further validation in human studies

3D-printed DIEP template — definition and creation from CTA imaging

DefinitionA patient-specific 3D-printed template of the abdominal wall/DIEP anatomy created from CTA imaging and 3D processing to indicate perforator positions and pedicle course

Creation workflowCTA imaging -> 3D software processing (eg, 3D Slicer, MeshMixer) -> desktop 3D printing (eg, Ultimaker) to produce a tactile template with perforator holes/lines

Clinical utilityTemplates accurately identified perforators and reduced intraoperative perforator identification time in a 20-patient series; surgeons found templates useful for pre-operative marking and planning

LimitationsPrinting time, material cost, and limited evidence from small series; further validation needed before broad adoption

Neurotization / nerve coaptation — definition and purpose

DefinitionSurgical technique connecting or coapting donor sensory nerves (eg, intercostal nerves) to recipient chest wall or flap nerves to restore sensation after reconstruction

Intended purposeAims to improve the rate, magnitude, and distribution of sensory recovery in reconstructed breasts and the nipple-areola complex (NAC)

Evidence summarySystematic reviews report pooled neurotization success ~90.6% with earlier and superior sensory recovery but note substantial heterogeneity and need for standardized outcome measures

neurotization / nerve coaptation — further definition for NAC and flap neurotization

NAC neurotizationCoaptation or grafting of sensory nerves to the nipple-areola complex during nipple-sparing mastectomy/reconstruction to preserve or improve nipple sensation

Reported outcomesOne study (n=78) reported 100% maintenance of NAC sensation after NSM with neurotization; other small studies reported diminished protective sensation in some patients

Testing modalitiesSensory outcomes assessed with Semmes-Weinstein Monofilaments, pressure/temperature thresholds, and patient-reported outcome tools (eg, BREAST-Q)

Evidence limitationsHeterogeneous methodologies, small sample sizes, and non-standardized sensory testing limit definitive conclusions; further multicenter standardized studies are needed

Semmes-Weinstein Monofilaments (SWM) — sensory testing tool definition

DefinitionSemmes-Weinstein Monofilaments (SWM) are an objective sensory testing tool used to quantify tactile pressure thresholds

Use in studiesSWM was the uniform objective measure in systematic reviews comparing neurotized versus non-neurotized free-flap reconstructions

Outcome interpretationLower mean pressure thresholds in neurotized patients indicate improved tactile sensitivity compared to controls in pooled analyses

Role in standardizationAuthors recommend standardized sensory testing (eg, SWM) and PROMs (BREAST-Q) for future studies assessing neurotization outcomes

OpenPayer

Breast Reconstructive Surgery

Coverage Criteria

Coding

Provider Actions & Requirements

Background

Definitions